Abstract
Rashid Riaz, MD, Leah Lande, MD, and Dana Zappetti, MD Synopsis: In this 2-year, multicenter, randomized, double-blind, placebo-controlled trial, the use of tiotropium in patients with chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease stage 1 and stage 2 disease resulted in improved forced expiratory volume in 1 second throughout the trial duration, reduced rate of decline in forced expiratory volume in 1 second after bronchodilator use over 24 months, decreased frequency of exacerbations, and improved quality of life assessments compared with placebo. However, it remains unclear whether the use of tiotropium alters the long-term disease course in patients with chronic obstructive pulmonary disease. Source: Yumin Zhou, Nan-shan Zhong, Xiaochen Li, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med 2017;377:923–935.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
